A listed company offering stem cell treatments to injured athletes is under fire for talking up the AFL's "approval" of its procedure and allegedly misleading the stock exchange. In August, Sydney-based biotech company Regeneus, which raised $12 million by listing on the stock market last year, put out a press release headed "ASX Announcement" which said the AFL "approved" the use of its liposuction-based stem cell procedure for injured players.
http://ift.tt/ZnMSIQ
http://ift.tt/ZnMSIQ
No comments:
Post a Comment